Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies Plc has reported a challenging fiscal year 2024, with a decrease in audited revenues but an increase in the sales pipeline towards the end. The company successfully raised funds for working capital and saw improved commercial activity post-period, including key collaborations and a first purchase order from a major diagnostics company. Fusion remains optimistic about future growth and does not plan to seek further cash through equity placement, as they work towards profitability.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
